"

M5彩票_首页_M5彩票官网拥有全球最顶尖的原生APP,每天为您提供千场精彩体育赛事,M5彩票_首页_M5彩票官网更有真人、彩票、电子老虎机、真人电子竞技游戏等多种娱乐方式选择,M5彩票_首页_M5彩票官网让您尽享娱乐、赛事投注等,且无后顾之忧!

  • "

    About Kawin

    POSITION:Home>News

    KW-136 in Combination with Sofosbuvir Under Phase 3 Trial

    Date:2017-05-31 12:29Source:Kawin TechnologyWriter:Kawin Technology

    In May 2017, Kawin Technology initiated a phase 3 trial program to investigate use of KW-136, an investigational DAA against HCV, in combination with sofosbuvir for treatment of pan-genotypic HCV infection. This regimen is expected to provide the first-in-China, all-oral, pan-genotypic treatment for HCV- infected patients, including those with cirrhosis.  

    M5彩票_首页_M5彩票官网